In this closing segment, Drs. Lovly and Shaw synthesize the most important lessons from the 7-year CROWN update, address the study's remaining limitations and unanswered questions, and reflect on what this data means for the broader landscape of ALK-positive NSCLC care — from treatment guidelines to payer decision-making to patient survivorship.
This segment brings together two essential threads — the broader context of lorlatinib's remarkable durability relative to earlier ALK inhibitors, and the practical, multidisciplinary strategies clinicians need to support patients on long-term therapy — while making a compelling case for why these data are directly relevant to community oncology practice.
This segment addresses one of the most practically important aspects of lorlatinib therapy — its distinct and manageable safety profile — and provides clinicians with actionable guidance on dose optimization strategies to support long-term treatment tolerability.
This segment introduces the Phase III CROWN study, providing essential background on its design and framing the remarkable significance of reporting 7-year follow-up data in the setting of advanced, stage 4 ALK-positive NSCLC.
This segment introduces the Phase III CROWN study, providing essential background on its design and framing the remarkable significance of reporting 7-year follow-up data in the setting of advanced, stage 4 ALK-positive NSCLC.
This segment dives into two of the most practically important questions facing clinicians who manage ALK-positive NSCLC: how to optimally test for ALK rearrangements, and how to select among the growing number of first-line treatment options available today.
This segment opens with foundational context on ALK-positive non-small cell lung cancer, establishing the clinical and scientific backdrop that makes this disease state — and its recent treatment advances — so compelling.
